enGene Therapeutics Inc. (ENGN) - Latest Market Data

Price & Market Data

Price: $1.48

Daily Change: -$0.0104 / 0.70%

Daily Range: $1.40 - $1.50

Market Cap: $96,464,832

Daily Volume: 4,347,714

Performance Metrics

1 Week: -81.75%

1 Month: -80.62%

3 Months: -84.89%

6 Months: -76.24%

1 Year: -51.52%

YTD: -84.05%

About enGene Therapeutics Inc. (ENGN)

Get current market data for enGene Therapeutics Inc. (ENGN). Price: 1.48, daily change: -$0.0104 / 0.70%. Market cap: 96,464,832. Performance YTD, 1-week, 3-month.

Company Details

Employees: 82

Sector: Commercial services

Industry: Miscellaneous commercial services

Country: Canada

Details

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Selected stocks

JFrog Ltd. (FROG)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Haoxi Health Technology Limited (HAO)

Wise Group plc (WSE)